AR042670A1 - Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal - Google Patents
Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominalInfo
- Publication number
- AR042670A1 AR042670A1 ARP030104848A ARP030104848A AR042670A1 AR 042670 A1 AR042670 A1 AR 042670A1 AR P030104848 A ARP030104848 A AR P030104848A AR P030104848 A ARP030104848 A AR P030104848A AR 042670 A1 AR042670 A1 AR 042670A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- group
- halogen
- heterocyclic
- chloride channel
- Prior art date
Links
- 108010062745 Chloride Channels Proteins 0.000 title abstract 3
- 102000011045 Chloride Channels Human genes 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003187 abdominal effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- -1 prostaglandin compound Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 206010000059 abdominal discomfort Diseases 0.000 abstract 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Uso de un abridor del canal de cloruro, en especial un compuesto de prostaglandina, para el tratamiento de malestar abdominal. Uso de un abridor del canal de cloruro, en especial un compuesto de prostaglandina, para el tratamiento de trastornos gastrointestinales funcionales. Reivindicación 2: El uso de acuerdo con la reivindicación 1, donde dicho compuesto de prostaglandina es el compuesto representado por la fórmula general (1), donde: L, M y N son átomo de hidrógeno, hidroxi, átomo de halógeno, alquilo inferior, hidroxialquilo (inferior), alcanoiloxi inferior u oxo, donde al menos una de L y M es un grupo diferente de hidrógeno, y el anillo de cinco miembros puede tener al menos un enlace doble; A es -CH3 o -CH2OH, -COCH2OH, -COOH o uno de sus derivados funcionales; B es un enlace simple, -CH2-CH2-, -CH=CH-, -C=C-, -CH2-CH2-CH2-, -CH=CH-CH2-, -CH2-CH=CH-, -C:::C-CH2- o -CH2-C:::C-; Z es un resto de grupo de fórmula (2) o un enlace simple, donde: R4 y R5 son hidrógeno, hidroxi, halógeno, alquilo inferior, alcoxi inferior o hidroxialquilo (inferior), donde R4 y R5 no son hidroxi y alcoxi inferior al mismo tiempo; R1 es un residuo hidrocarbonado alifático inferior o medio bivalente saturado o insaturado que está insustituido o sustituido con halógeno, alquilo, hidroxi, oxo, arilo o grupo heterocíclico, y al menos uno de los átomos de carbono en el hidrocarburo alifático está opcionalmente sustituido con oxígeno, nitrógeno o azufre; y Ra es un residuo hidrocarbonado alifático inferior o medio saturado o insaturado que está insustituido o sustituido con halógeno, oxo, hidroxi, alquilo inferior, alcoxi inferior, alcanoiloxi inferior, cicloalquilo (inferior), cicloalquiloxi (inferior), arilo, ariloxi, grupo heterocíclico o grupo heterocíclico-oxi; alcoxi inferior; alcanoiloxi inferior; cicloalquilo (inferior); cicloalquiloxi (inferior); arilo; ariloxi; grupo heterocíclico; grupo heterocíclico-oxi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43646302P | 2002-12-27 | 2002-12-27 | |
| US43646202P | 2002-12-27 | 2002-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042670A1 true AR042670A1 (es) | 2005-06-29 |
Family
ID=32717850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104848A AR042670A1 (es) | 2002-12-27 | 2003-12-29 | Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7795312B2 (es) |
| EP (2) | EP2281564A3 (es) |
| JP (2) | JP4889219B2 (es) |
| KR (2) | KR101164838B1 (es) |
| CN (1) | CN1753680B (es) |
| AR (1) | AR042670A1 (es) |
| AU (1) | AU2003292556B2 (es) |
| BR (1) | BRPI0317740B8 (es) |
| CA (1) | CA2510051C (es) |
| ES (1) | ES2591252T3 (es) |
| MX (1) | MXPA05006981A (es) |
| NO (1) | NO335441B1 (es) |
| NZ (1) | NZ541110A (es) |
| TW (1) | TWI336254B (es) |
| WO (1) | WO2004060377A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR037524A1 (es) * | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
| NZ539582A (en) * | 2002-10-23 | 2007-07-27 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
| DE602004030245D1 (de) * | 2003-07-03 | 2011-01-05 | Sucampo Ag | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner |
| TWI387454B (zh) * | 2004-09-02 | 2013-03-01 | 蘇坎波公司 | 治療胃腸道疾病之方法及組成物 |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| CN101180096B (zh) * | 2005-03-21 | 2015-04-22 | 苏坎波公司 | 用于治疗粘膜疾病的方法和组合物 |
| DK1871380T3 (da) * | 2005-04-12 | 2011-11-21 | Sucampo Ag | Kombineret anvendelse af prostaglandinforbindelse og protonpumpeinhibitor til behandlingen af gastrointestinale lidelser |
| WO2008029949A1 (en) * | 2006-09-06 | 2008-03-13 | Sucampo Ag | Method and composition for promoting gastrointestinal bicarbonate secretion |
| EP2114411A2 (en) * | 2007-02-27 | 2009-11-11 | Sucampo AG | Composition and method for protecting mitochondria |
| US20090012165A1 (en) * | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
| US20090030072A1 (en) | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
| AU2010295464B2 (en) * | 2009-09-18 | 2015-11-26 | Merck Sharp & Dohme Corp. | Use of opioid receptor antagonist for gastrointestinal tract disorders |
| IT1402047B1 (it) * | 2010-10-19 | 2013-08-28 | Cross Pharma Sa | Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA2870252A1 (en) * | 2012-04-23 | 2013-10-31 | Sucampo Ag | Method for treating irritable bowel syndrome with diarrhea |
| JP6461803B2 (ja) | 2012-10-15 | 2019-01-30 | エピザイム，インコーポレイティド | 置換ベンゼン化合物 |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1581886A (en) * | 1977-05-26 | 1980-12-31 | May & Baker Ltd | Prostanol derivatives |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| US5317032A (en) * | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| JPH0681728B2 (ja) * | 1987-10-02 | 1994-10-19 | 株式会社上野製薬応用研究所 | 下 剤 |
| JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体 |
| TW249226B (es) | 1990-04-04 | 1995-06-11 | Aderk Ueno Kk | |
| DE69130586T2 (de) * | 1990-05-01 | 1999-06-17 | R-Tech Ueno, Ltd., Osaka | Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| DK0857718T3 (da) | 1996-06-10 | 2002-12-16 | Sucampo Ag | Endothelinantagonist |
| US6046239A (en) * | 1997-08-05 | 2000-04-04 | American Home Products Corporation | Anthranilic acid analogs |
| AU739343B2 (en) * | 1997-11-28 | 2001-10-11 | Sucampo Ag | Endothelin antagonist |
| US6492417B1 (en) * | 1997-12-22 | 2002-12-10 | Alcon Manufacturing, Ltd. | 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists |
| AR026046A1 (es) * | 1999-10-15 | 2002-12-26 | R Tech Ueno Ltd | NUEVA COMPOSICIoN Y MÉTODO PARA ESTABILIZAR LA MISMA |
| ATE433754T1 (de) * | 2000-04-06 | 2009-07-15 | Sucampo Ag | Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| ATE387204T1 (de) | 2001-05-18 | 2008-03-15 | Sucampo Ag | Zusammensetzung mit induzierendem kathartischen effekt |
| BR0212233A (pt) | 2001-08-31 | 2004-10-05 | Sucampo Ag | Abridor de canal de cloreto |
| AR037524A1 (es) * | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
| US7732487B2 (en) * | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
-
2003
- 2003-12-26 BR BRPI0317740A patent/BRPI0317740B8/pt not_active IP Right Cessation
- 2003-12-26 ES ES03768289.5T patent/ES2591252T3/es not_active Expired - Lifetime
- 2003-12-26 NZ NZ541110A patent/NZ541110A/en not_active IP Right Cessation
- 2003-12-26 WO PCT/JP2003/016857 patent/WO2004060377A1/en not_active Ceased
- 2003-12-26 EP EP10177588A patent/EP2281564A3/en not_active Withdrawn
- 2003-12-26 AU AU2003292556A patent/AU2003292556B2/en not_active Expired
- 2003-12-26 EP EP03768289.5A patent/EP1575596B1/en not_active Expired - Lifetime
- 2003-12-26 KR KR1020057012162A patent/KR101164838B1/ko not_active Expired - Lifetime
- 2003-12-26 CA CA2510051A patent/CA2510051C/en not_active Expired - Lifetime
- 2003-12-26 JP JP2004564537A patent/JP4889219B2/ja not_active Expired - Lifetime
- 2003-12-26 TW TW092136988A patent/TWI336254B/zh not_active IP Right Cessation
- 2003-12-26 MX MXPA05006981A patent/MXPA05006981A/es active IP Right Grant
- 2003-12-26 KR KR1020127006692A patent/KR20120045051A/ko not_active Ceased
- 2003-12-26 CN CN2003801099014A patent/CN1753680B/zh not_active Expired - Lifetime
- 2003-12-29 AR ARP030104848A patent/AR042670A1/es not_active Application Discontinuation
- 2003-12-29 US US10/745,689 patent/US7795312B2/en not_active Expired - Lifetime
-
2005
- 2005-07-26 NO NO20053623A patent/NO335441B1/no not_active IP Right Cessation
-
2010
- 2010-08-02 US US12/848,597 patent/US20100298424A1/en not_active Abandoned
-
2011
- 2011-11-01 JP JP2011240314A patent/JP2012031202A/ja active Pending
-
2013
- 2013-03-18 US US13/845,353 patent/US20130217770A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2510051A1 (en) | 2004-07-22 |
| EP2281564A3 (en) | 2012-09-05 |
| BRPI0317740B8 (pt) | 2021-05-25 |
| JP4889219B2 (ja) | 2012-03-07 |
| WO2004060377A1 (en) | 2004-07-22 |
| EP1575596A1 (en) | 2005-09-21 |
| KR101164838B1 (ko) | 2012-07-11 |
| ES2591252T3 (es) | 2016-11-25 |
| TW200418491A (en) | 2004-10-01 |
| NO20053623D0 (no) | 2005-07-26 |
| KR20050086950A (ko) | 2005-08-30 |
| NO20053623L (no) | 2005-09-26 |
| AU2003292556A1 (en) | 2004-07-29 |
| JP2012031202A (ja) | 2012-02-16 |
| US7795312B2 (en) | 2010-09-14 |
| CA2510051C (en) | 2016-07-05 |
| KR20120045051A (ko) | 2012-05-08 |
| TWI336254B (en) | 2011-01-21 |
| EP1575596B1 (en) | 2016-06-22 |
| MXPA05006981A (es) | 2005-12-14 |
| US20040138308A1 (en) | 2004-07-15 |
| NZ541110A (en) | 2008-11-28 |
| AU2003292556B2 (en) | 2009-09-10 |
| CN1753680B (zh) | 2010-12-08 |
| NO335441B1 (no) | 2014-12-15 |
| CN1753680A (zh) | 2006-03-29 |
| BRPI0317740B1 (pt) | 2018-09-18 |
| US20100298424A1 (en) | 2010-11-25 |
| JP2006513232A (ja) | 2006-04-20 |
| US20130217770A1 (en) | 2013-08-22 |
| BR0317740A (pt) | 2005-11-22 |
| EP2281564A2 (en) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042670A1 (es) | Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal | |
| AR100696A2 (es) | Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas | |
| AR036391A1 (es) | Uso de un compuesto de prostaglandina para preparar una composicion farmaceutica para abrir los canales de cic en un mamifero y compuestos de prostaglandina | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| CL2020000029A1 (es) | Nuevos compuestos de carboxamida sulfonamida. | |
| CO2020009225A2 (es) | Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco | |
| CO5590915A2 (es) | Derivados de piperidina como antagonistas nk1 ( receptor del neuropeptido neuroquinina-1) con actividad antagonista superior en tratamientos de trastornos fisiologicos y disminucion de efectos colaterales | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| DK1585739T3 (da) | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer | |
| AR073158A1 (es) | Metodo y composicion para modular el crecimiento de celulas madre | |
| CY1111493T1 (el) | Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης | |
| ECSP066298A (es) | Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3) | |
| CL2021001039A1 (es) | Conjugados de fármaco-anticuerpo que comprenden derivados de la ecteinascidina. | |
| CO6220952A2 (es) | Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
| AR066962A1 (es) | Compuesto heterociclico fusionado | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| UY28141A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| AR044650A1 (es) | Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa. | |
| CO5031247A1 (es) | Compuestos triciclicos sustituidos | |
| AR060427A1 (es) | Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares | |
| CO5550437A2 (es) | Compuestos quimicos | |
| AR111272A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con arilo farmacológicamente activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |